相关临床试验
29
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1962
进行中（未招募）
4
13.8%
已完成
14
48.3%
尚未招募
2
6.9%
招募中
9
31.0%
暂无批准数据
- BillionToOne's Northstar Select liquid biopsy has been selected for the LC-SCRUM-TRY study at Japan's National Cancer Center Hospital East, focusing on treatment-resistant non-small cell lung cancer. - The ultra-sensitive test demonstrated superior performance in head-to-head comparisons, detecting genetic variants at frequencies as low as 0.15% using proprietary single-molecule NGS technology. - The selection addresses critical barriers in obtaining tissue biopsies from drug-resistant tumors, offering a non-invasive alternative for comprehensive genomic profiling. - The study aims to better characterize drug-resistant cancers and identify more effective therapies for patients with treatment-resistant disease.
- Myriad Genetics will launch its Precise MRD assay for limited clinical use in March 2026, starting with breast cancer followed by colorectal and renal cancers later in the year. - The ultrasensitive test demonstrates exceptional performance with 93% baseline sensitivity in breast cancer and 100% baseline detection in colorectal cancer patients. - Clinical studies show the assay can detect circulating tumor DNA at one part-per-million levels, enabling early prediction of treatment response and disease recurrence. - The whole-genome sequencing-based test represents a significant advancement in molecular residual disease monitoring for precision oncology applications.
- Lunit's SCOPE IO artificial intelligence platform successfully predicted immunotherapy response in three major cancer types through analysis of routine histopathology slides presented at ESMO 2025. - In colorectal cancer trials, biomarker-high patients showed significantly improved progression-free survival and overall survival when treated with atezolizumab combinations compared to biomarker-low patients. - The AI tool demonstrated 60.5% response rates versus 23.2% for inflamed versus non-inflamed tumors in advanced clear cell renal cell carcinoma patients treated with nivolumab plus ipilimumab. - Validation studies across lung, kidney, and colorectal cancers support the platform's potential to guide personalized immunotherapy treatment selection in clinical practice.
- Myriad Genetics delivered second quarter 2025 revenue of $213.1 million, beating analyst estimates by 5.5% and raising full-year revenue guidance to $823 million at the midpoint. - The company announced a strategic pivot to focus investments on the Cancer Care Continuum, including plans for an early access launch of its proprietary ultra-sensitive MRD test in the first half of 2026. - Hereditary cancer testing showed strong momentum with 14% year-over-year growth in MyRisk with RiskScore testing volume in oncology, while gross margin improved 140 basis points to 71.5%. - Myriad secured a new $200 million credit facility with OrbiMed to support its strategic transformation and long-term growth objectives.
- Flatiron Health's international oncology research network has tripled in size over the past year, now encompassing more than 30 partnerships across the UK, Germany, and Japan. - The expansion brings Flatiron's total patient database above 5 million records, with new partnerships including major academic medical centers and national cancer centers in each country. - The company established Flatiron FORUM, a global consortium addressing data transportability challenges to support multinational cancer research and regulatory decisions. - Seven research studies using multinational real-world data have been completed within the past two years, demonstrating the platform's capability for cross-country cohort analyses.
- A Phase I clinical trial is evaluating AP8901, a novel non-viral CAR-T cell therapy targeting EPHB4 receptor-expressing solid tumors including Ewing sarcoma. - The therapy uses innovative piggyBac transposon and genetically modified feeder cell methods to enable stable CAR protein expression while preventing T cell exhaustion. - AP8901 demonstrated therapeutic efficacy and tolerability in preclinical studies using rhabdomyosarcoma mouse models. - The single-center, dose-escalation study will assess safety, tolerability, and preliminary anti-tumor activity in patients with metastatic or recurrent solid tumors.
- Lunit will present 12 studies at ASCO 2025 showcasing AI-powered digital pathology solutions for precision oncology applications. - A key study with Japan's National Cancer Center demonstrated AI-enhanced HER2 analysis in biliary tract cancer, identifying additional responders to trastuzumab deruxtecan with 50% objective response rate. - AI-powered PD-L1 evaluation showed 70% concordance with expert pathologists and identified 231 additional immunotherapy candidates among 949 lung cancer patients. - Research includes novel AI models for predicting CLDN18.2 expression in gastric cancer and comprehensive tumor microenvironment analysis across multiple cancer types.
- Phase 3 ALTAIR study reveals Lonsurf (trifluridine/tipiracil) significantly extended disease-free survival to 9.76 months versus 3.96 months with placebo in stage 4 colorectal cancer patients. - While the overall trial population showed no statistically significant improvement, patients with higher baseline tumor markers demonstrated stronger benefits from Lonsurf treatment. - The drug maintained a manageable safety profile with no new safety signals, though 73% of Lonsurf-treated patients experienced grade 3 or worse side effects.
